Adaptive Biotechnologies/$ADPT
1D1W1MYTD1Y5YMAX
Capital at risk
About Adaptive Biotechnologies
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
- Ticker
- $ADPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 624
- Headquarters
- Seattle, United States
- Website
- www.adaptivebiotech.com
ADPT Metrics
BasicAdvanced
$3.9B
-
-$0.41
2.09
-
Price and volume
Market cap
$3.9B
Beta
2.09
52-week high
$26.87
52-week low
$12.00
Average daily volume
2.1M
Financial strength
Current ratio
4.795
Quick ratio
4.489
Long term debt to equity
266.607
Total debt to equity
272.464
Interest coverage (TTM)
-3.26%
Profitability
EBITDA (TTM)
-21.327
Gross margin (TTM)
46.94%
Net profit margin (TTM)
-20.73%
Operating margin (TTM)
-12.16%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-4.12%
Return on equity (TTM)
-38.76%
Valuation
Price to revenue (TTM)
12.21
Price to book
26.97
Price to tangible book (TTM)
167.14
Price to free cash flow (TTM)
-156.515
Free cash flow yield (TTM)
-0.64%
Free cash flow per share (TTM)
-0.155
Growth
Revenue change (TTM)
50.13%
Earnings per share change (TTM)
-49.41%
3-year revenue growth (CAGR)
17.56%
3-year earnings per share growth (CAGR)
-32.39%
What the Analysts think about ADPT
Analyst ratings (Buy, Hold, Sell) for Adaptive Biotechnologies stock.
Analyst projections of the future price of Adaptive Biotechnologies stock.
Bulls say / Bears say
MRD is showing strong commercial momentum: Q2 2026 MRD revenue increased 33% year over year to $66.2 million, while clonoSEQ test volume rose 43% to 36,111 tests. (Morningstar)
Operating leverage is improving as growth outpaces expense expansion: Q2 adjusted EBITDA loss narrowed to $0.7 million from $7.2 million a year earlier, despite continued investment in the business. (Morningstar)
Separating the profitable MRD diagnostics operation from Immune Medicine could sharpen strategic focus and allow investors to value the clonoSEQ-led business more directly, while potentially giving the discovery platform access to a better-suited capital structure or partner. (Reuters; Adaptive Biotechnologies)
Profitability remains fragile: Q2 2026 revenue rose 22% year over year to $71.6 million, but GAAP net loss widened to $39.9 million from $25.6 million, partly because of the OrbiMed settlement. (Morningstar)
The $300 million zero-coupon convertible-notes financing improves liquidity but adds future repayment obligations and potential shareholder dilution, even after a capped-call transaction and a $25 million share repurchase. (Adaptive Biotechnologies)
The planned separation of Immune Medicine introduces execution and funding uncertainty: Adaptive said it was still evaluating alternatives and gave no assurance that a transaction or other outcome would occur, while the business has faced revenue pressure after the Genentech agreement ended. (Reuters; SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
ADPT Financial Performance
Revenues and expenses
ADPT Earnings Performance
Company profitability
Upcoming events
No upcoming events
ADPT News
AllArticlesVideos
Funds containing ADPT
AllUSDEURGBP
Fund name | Fund size | $ADPT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.40% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.40% |
iShares Healthcare Innovation£DRDR | £1B | 0.40% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.25% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.25% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.